Skinbiotherapeutics Share Discussion Threads

[talkingtrade] 03/5/2017 09:46

Could return to 9p IPO

[manc10] 03/5/2017 08:30

down again

[ibug] 02/5/2017 14:41

On the rise as the oscillation continues, once the pivoting stops then we should start seeing an upward step channel forming imo.

[rubberbullets] 29/4/2017 13:45

5p next stop

[slartybartfaster] 29/4/2017 13:42

i dont see your logic this going to 9p bid. ipo was 9p fine, but it opened at 13.40ish and went as high as 16.25p. stops have been triggered for sure. for this to go to 9p bid would suggest seneca are still flipping, which makes no sense much below current levels. hope youre right though coz id like a few more to go with my nibble and free to come and hold for a few years.

[krobertson878] 28/4/2017 20:29

Get your bids on at 9p in this one.

[whl2] 28/4/2017 18:43

doubt Seneca will still hold 14.6% They shafted OPTI on the last placing, got new placing shares and sold the ones they held - can't stand them

[ibug] 28/4/2017 16:54

This is quite interesting:

Significant Shareholders

As at 5th April 2017, significant shareholders that hold more than 3% of the share capital of SkinBioTherapeutics plc, and shareholdings of any other directors are detailed below:
Number Ordinary Shares %


OptiBiotix Health Plc 49,794,190 41.9%
Seneca Partners Limited 17,388,889 14.6%
The University of Manchester 8,511,438 7.2%
Dr. Catherine O'Neill 5,256,989 4.4%
Professor Andrew McBain 5,201,434 4.4%

[peps83] 28/4/2017 13:46

Resistance at 11p?

[ibug] 25/4/2017 12:30

Interview with SOH regarding SBTX:

OptiBiotix Health PLC (LON:OPTI) Q&A with CEO Stephen O’Hara: AIM Listing of Skinbiotherapeutics PLC
Posted by: Amilia Stone 25th April 2017



OptiBiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara caught up with DirectorsTalk for an exclusive interview to discuss the listing of SkinBiotherapeutics PLC onto the AIM market, what this means for shareholders and how it fits in with OptiBiotix Health’s overall strategy

Q1: We’ve just seen the launch of SkinBiotherapeutics PLC (LON:SBTX) separately on AIM, can you explain the rationale behind this?
A1: Yes, sure. Just after listing OptiBiotix in August 2014 it became clear to me that the microbiome space was developing very rapidly and there was a window of opportunity for OptiBiotix to capitalise on our first move advantage and acquire IP in other areas in the microbiome space. There were two areas of particular interest, one was the skin microbiome and the second was the role of the microbiome in cognitive health, that is in stress, anxiety, mood etc., now, we’re still exploring opportunities in cognitive health and we’ll update shareholders if that opportunity materialises.
Moving on to skin, in terms of the skin microbiome, I’ve spent 12 months identifying and accessing skin technology around the world before I finally met up with Professor Andrew McBain and Dr Catherine O’Neill in early 2015 at Manchester University. I was really impressed with Manchester University, I was impressed with their expertise, their facilities and their links to industry in particular the skin field and so I set about acquiring the rights to the technology. This took 12 months and in March 2016 we reached an agreement to acquire the IP from Manchester University for £250,000 and we set up a joint venture company called SkinBiotix Limited which OptiBiotix own 50%. However, it became clear to myself and the Board that the opportunity offered by Skin and its potential future value was not really transparent to shareholders in OptiBiotix and it’s not surprising really considering that as a young company, we’ve only been on the Stock Market for just over 2 years, we have quite a diversity of IP and quite a diversity of commercial relationships across a number of microbiome areas. There’s a reason for this, whilst this approach has complexity, it’s been designed to mitigate development risk in an evolving scientific field and provide a cost-effective way to build overlapping IP and exploit the many opportunities offered by the microbiome.


So, it terms of listing Skin, the listing of SkinBiotherapeutics materialises the value of this part of the business so it’s now transparent to shareholders in OptiBiotix. OptiBiotix now owns 41.9% of a company valued and listed at £11 million which was risen over the last few days, the first few days of trading, to be £16-17 million so this means that OptiBiotix shareholders now have a significant shareholding, 42%, in an appreciating asset. More importantly, SkinBiotherapeutics has £4.5 million worth of cash to build future value in the business from these development programmes, which, similar to OptiBiotix, have targeted a very large consumer markets. So, I think it’s a great opportunity in a very exciting space.

[ibug] 25/4/2017 11:15

Finally, we are pleased with the successful admission of SkinBiotherapeutics plc to AIM in April 2017, representing a substantial return on our initial investment."

[judijudi] 25/4/2017 10:04

ibug,
A tad premature

[ibug] 24/4/2017 09:53

The trend from last Friday continues with the bounce rise back....excellent.

[t 34] 24/4/2017 09:33

Investors presentation for opti tomorrow in the city.

[moneytree1] 24/4/2017 09:19

1 Code for the believers..news on the way?

[slartybartfaster] 22/4/2017 14:35

oh look a tw troll spamming the tw related threads. my view is avoid taking advice from a convict, especially a northern manc one and sell if the company youre invested in is flagged as a fraud because the hit rate is 100%. Which fraud di you lose your shirt on opo? Tit.

[ibug] 21/4/2017 15:15

Nice to see the stock roaring back to a higher share price value. At these levels the share price offers a good opportunity for much higher returns imo.

[love it] 21/4/2017 15:12

Had some at 12.5p could not get many but looks like it's going to bounce well.

[ibug] 21/4/2017 09:46

Some relevant and interesting articles in this months latest edition of Microbiome:



The Human Microbiome: Beyond the Gut

Tuesday May 5, 2015
2:30 - 4:00 p.m. Eastern Time
View The Video Now

The human body hosts myriad distinct bacterial colonies that play important functions in both health and disease. These dynamic microbial colonies fluctuate over time and even form niche colonies in close proximity to one another. This webinar will highlight new research on the human microbiome and how this knowledge is being used to understand health and disease. The panelists will discuss advances in research on lung and skin microbiome. Attendees will have an opportunity to interact with the experts, ask questions, and seek advice on topics that are unique to their research.

[bernieboy] 21/4/2017 09:39

Who knows. Somebody a few weeks back said I wouldn't be able to buy back in at under 13.9 when I sold at just under 17. Sub 11 is possible but most (I suspect) are looking at this as a long term hold like Opti. I just saw an opportunity to ride the wave of euphoria on listing and used it to make a few bucks. Will get more if it goes lower if funds allow......